Interferon Alpha and Cytosine Arabinoside in the Treatment of Chronic Myelogenous Leukemia
暂无分享,去创建一个
R. Bouabdallah | F. Bauters | N. Ifrah | J. Harousseau | F. Guilhot | B. Christian | F. Maloisel | J. Brière | M. Navarro | M. Michallet | D. Guyotat | A. Guerci | J. Abgrall | M. Blanc | P. Morice | G. Tertian | J. Vilque
[1] P. Cony-Makhoul,et al. Response to recombinant interferon alpha in patients with chronic myelogenous leukemia in a single center: results and analysis of predictive factors. , 1995, Leukemia.
[2] S. Richards,et al. UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response , 1995, The Lancet.
[3] H. Kantarjian,et al. Prolonged Survival in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon- Therapy , 1995, Annals of Internal Medicine.
[4] S. Cannistra,et al. Hematologic remission and cytogenetic improvement after treatment of stable‐phase chronic myelogenous leukemia with continuous infusion of low‐dose cytarabine , 1993, American journal of hematology.
[5] R. Kurzrock,et al. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. , 1991, Annals of internal medicine.
[6] C. Slapak,et al. Interferon protects normal human granulocyte/macrophage colony-forming cells from Ara-C cytotoxicity. , 1990, Journal of biological response modifiers.
[7] H. Kantarjian,et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. , 1986, The New England journal of medicine.
[8] J. Griffin,et al. Clinical pharmacology of low-dose cytosine arabinoside , 1985 .
[9] S. Sallan,et al. Pharmacokinetics of continuous intravenous and subcutaneous infusions of cytosine arabinoside. , 1982, Blood.
[10] A. Efira,et al. Sensitivity of myeloid progenitor cells in healthy subjects and patients with chronic myeloid leukemia to chemotherapeutic agents. , 1981, Journal of the National Cancer Institute.
[11] J. Huret,et al. Cytogenetic Remissions in Chronic Myelogenous Leukemia Using Interferon Alpha-2a and Hydroxyurea with or without Low-Dose Cytosine Arabinoside. , 1991, Leukemia & lymphoma.
[12] S. Bigner,et al. Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemia. , 1988, Leukemia research.
[13] S. Leong,et al. Preferential inhibition by cytarabine of CFU‐GM from patients with chronic granulocytic leukemia , 1987, Cancer.